Blood Cell Gene Changes and Heart Damage After a Severe Heart Attack
Looks at whether blood gene changes relate to heart damage in heart attack patients.
Plain-language title generated from the registry record
Registry title: Clonal Hematopoiesis of Indeterminate Potential and Infarct Severity in ST-Elevation Myocardial Infarction
Key facts
- Where
- Innsbruck, AustriaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07615023, who can take part
Where in Austria
- Medical University of InnsbruckInnsbruck, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical University Innsbruck
- Trial code
- NCT07615023
- Record updated
- 9 October 2026
- Original description
Clonal Hematopoiesis of Indeterminate Potential (CHIP) refers to the age-related expansion of hematopoietic stem cell clones carrying somatic mutations in leukemia-associated driver genes (e.g., DNMT3A, TET2, ASXL1) in the absence of a hematological malignancy. CHIP has been identified as an independent cardiovascular risk factor associated with increased rates of myocardial infarction, stroke, and cardiovascular mortality, likely mediated through enhanced inflammatory signaling in mutant macrophages and monocytes.Read full original descriptionShow less
Clonal Hematopoiesis of Indeterminate Potential and Infarct Severity in ST-Elevation Myocardial Infarction
Clonal Hematopoiesis of Indeterminate Potential (CHIP) refers to the age-related expansion of hematopoietic stem cell clones carrying somatic mutations in leukemia-associated driver genes (e.g., DNMT3A, TET2, ASXL1) in the absence of a hematological malignancy. CHIP has been identified as an independent cardiovascular risk factor associated with increased rates of myocardial infarction, stroke, and cardiovascular mortality, likely mediated through enhanced inflammatory signaling in mutant macrophages and monocytes.
ST-elevation myocardial infarction (STEMI) is a life-threatening emergency requiring immediate reperfusion by primary percutaneous coronary intervention (PCI). Despite successful reperfusion, adverse cardiac remodeling and heart failure may occur depending on myocardial injury severity, microvascular obstruction (MVO), and intramyocardial hemorrhage (IMH) - phenomena substantially driven by ischemia-reperfusion injury and the inflammatory response.
The CHIP in STEMI study is a prospective, observational, single-center cohort study at the Medical University of Innsbruck investigating whether CHIP - detected by targeted next-generation sequencing - is associated with greater infarct severity and worse cardiac outcomes in STEMI patients undergoing primary PCI. The primary endpoint is the presence of MVO and/or IMH on cardiac MRI (CMR) at 5±2 days post-PCI. Secondary endpoints include infarct size, left and right ventricular function, major adverse cardiovascular events (MACE), and immune cell transcriptome profiling by single-cell RNA sequencing.
350 patients (18-75 years, minimum 90 female) will be enrolled over 36 months and followed for 4 years (2026-2030).
Inclusion: Diagnosis of first acute ST-elevation myocardial infarction according to current European Society of Cardiology guidelines; Symptoms consistent with ST-elevation myocardial infarction lasting more than 30 minutes and less than 12 hours before primary percutaneous coronary intervention; Treatment with primary percutaneous coronary intervention; Age 18 to 75 years; Written informed consent.
Exclusion: Prior myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention; Prior oncologic treatment with chemotherapy, radiotherapy, or radioisotopes; Persistent hemodynamic instability, Killip class greater than 2 including cardiogenic shock, or resuscitated cardiac arrest not allowing cardiac magnetic resonance imaging; Known active or prior malignancy, including hematologic malignancies or myelodysplastic syndromes; Chronic viral infection associated with systemic inflammation; Active autoimmune disease or chronic systemic inflammatory disorder; Contraindication to cardiac magnetic resonance imaging; Pre-ST-elevation myocardial infarction life expectancy of less than 1 year; Abnormal baseline complete blood count with clinically significant cytopenia, defined as leukocytes less than 3.0 x 10\^9/L, platelets less than 100 x 10\^9/L, or hemoglobin less than 10 g/dL; Chronic kidney disease with creatinine clearance less than 30 mL/min/1.73 m2; Participation in an interventional trial; Limited possibility to attend follow-up examinations, for example residence abroad; Pregnancy.